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Project Summary 
Background, Significance: 
The need to create global metrics for outcomes in the field of ophthalmology remains 
great as they can be used to drive patient monitoring and quality improvement 
activities at eye care centers. Presently, several patient-reported outcomes (PROs) for 
glaucoma have been validated in Indian populations. 
 
Gothwal, VK, et al. utilized the Glaucoma Quality of Life-15 (GQL-15) questionnaire 
with 198 LV Prasad Institute patients classified as mild, moderate, and severe visual 
field loss groups (1). Due to poorly fitting questions via Rasch Analysis, the 
questionnaire was pared down to 10 questions and named the Glaucoma Activity 
Limitation-10 (GAL-10) questionnaire. This cross-sectional study demonstrated a 
consistent pattern of worsening function with increasing visual field loss; however, the 
utility of the questionnaire in patients with mild disease was poor. 
 
Additionally, the 33-item Indian Visual Functioning Questionnaire (IND-VFQ) was 
developed to measure the visual symptoms, psychosocial impact, and functioning of 
patients with a broad range of eye conditions (2). Limited additional studies utilizing 
the IND-VFQ in glaucoma patients have been published. Most notably, Arora, et al. 
utilized it in a longitudinal study of 62 patients newly diagnosed with moderate to 
severe primary glaucoma (3). 
 
Spaeth and colleagues have compared the validity of clinical measures, performance-
based measures, and PRO measures to detect changes in outcomes that are relevant to 
patients with glaucoma in Philadelphia, Pennsylvania, USA (4, 5). The 4-item 
Compressed Assessment of Ability Related to Vision (CAARV), a performance-based 
measure (PBM), was adapted from the 9-item Assessment of Disability Related to 
Vision (ADREV) (6). These instruments can be easily modified to suit other cultural 
and linguistic contexts and have been shown to have excellent face and content 
validity. 
 
A PBM has yet to be validated and utilized in an Indian population. This measure can 
provide an objective assessment of how glaucoma affects the daily function of patients, 
beyond subjective PROs and traditional clinical measures. This study aims to validate 
the CAARV for a south Indian patient population with glaucoma and to determine the 
relationship between CAARV results and the clinical and subjective measures used in 
glaucoma patients. We hypothesize that this instrument will demonstrate adequate 
validity within this population and correlate with existing PROs and clinical measures. 
 
Patient Recruitment: 
With the assistance of on-site research colleagues, participants will be enrolled at 
Aravind Eye Hospital (AEH) - Madurai. Participants will be identified during the 
cross-sectional data collection period in February 2018. Demographics will be collected 
and past medical and ocular history will be reviewed in the medical record. 
 
Inclusion criteria are: individuals receiving care at AEH with glaucoma but without 
other ocular comorbidities. Visual loss can range from none to far-advanced. The 
glaucoma patients will have already been examined and diagnosed at AEH by a 
glaucoma specialist based on optic nerve examination, repeatable visual field (VF) 
defects, and the absence of other causes of optic neuropathy. Patients who have 
primary open-angle glaucoma, primary angle-closure glaucoma, “normal pressure 
glaucoma,” pseudoexfoliative glaucoma, pigmentary glaucoma, inflammatory 
glaucoma, neovascular glaucoma, traumatic glaucoma, plateau iris syndrome, or 
ocular hypertension are eligible to participate. 
 
The patients will be subdivided into four categories based on the Hodapp-Parish-
Anderson System: HPA-0 (none), HPA-1 (mild), HPA-2 (moderate), HPA-3 (severe) 
(7). These categories are based on the amount of field damage as demonstrated by the 
visual field loss recorded by Humphrey Visual Field perimetry. A grid has been 
developed to include different amounts of visual field loss, and 40-60 patients will be 
recruited within each category. Patients will not be discriminated based on visual 
acuity, although it will be collected as an additional data point. As eligible cases are 
enrolled, the grid block will be updated with subject fit. As the study progresses, 
patients will be selected depending upon which blocks on the grid were still not filled. 
 
Exclusion criteria are: Inability to understand and respond to spoken Tamil or English; 
ocular surgery within 3 months; laser treatment within 1 month; significant 
neuromuscular problems; or medical comorbidities that prevent completion of the 
study protocol, such as diagnosed cognitive impairment (e.g. dementia), or diagnosed 
severe mental illness (e.g. schizophrenia). " 
 
Action Items/Outcome 
"Experimental Methods and Design:  
Patient participants meeting study criteria will be consented and enrolled in the study. 
Approximately 200 patients will be recruited to provide adequate item calibrations (8). 
 
Our project aims to cross-sectionally validate several instruments in a heterogeneous 
population of patients with glaucoma in southern India. Patient demographics will be 
collected along with four main outcomes: 
1) Responses to the IND-VFQ 33 questionnaire (2). 
2) 7-item glaucoma symptom checklist (9). 
3) Compressed Assessment of Ability Related to Vision (CAARV). The CAARV 
consists of four tasks: finding items in a room; sign recognition; facial recognition; and 
motion detection. This test will be modified for the South Indian population with 
appropriate signs and facial expressions (6). 
4) Clinical data will be collected through chart review. These data include: visual 
acuity; visual field indices; and SPARCS contrast sensitivity (10). 
 
Statistical Analyses: 
Descriptive statistics will be computed for demographics, clinical measures, PBM, and 
quality of life measures. Rasch analysis will be used to characterize each patient based 
on total CAARV score. Construct validity will be evaluated by examining the 
correlations between the CAARV scores, the various clinical measures of visual 
function, and the other PROs. " 
 
Conclusion/Reflection 
Anticipated Results and Potential Problems: 
We anticipate that these instruments will demonstrate adequate validity in a South 
Indian population with glaucoma. Once validated in February 2018, a longitudinal 
cohort study may be pursued to test whether outcome measures such as IND-VFQ, 
CAARV, or SPARCS contrast sensitivity are able to capture changes associated with 
glaucoma progression that may be more relevant to quality of life and functioning 
than standard clinical measures. 
 
Potential problems relate primarily to logistics, particularly the patient recruitment 
and the translation of the CAARV to Tamil and the south Indian context. 
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